Genetic database software as medical devices

This article provides a primer on medical device regulations in the United States, Europe, and Canada. Software tools are being developed and shared globally to enhance the accessibility and usefulness of genomic databases. Interactive software tools, such as email or mobile alert systems providing variant classification updates, are opportunities to democratize access to genomic data beyond laboratories and clinicians. Uncertainty over the reliability of outputs, however, raises concerns about potential harms to patients, especially where software is accessible to lay users. Developers may also need to contend with unfamiliar medical device regulations. The application of regulatory controls to genomic software could improve patient and user safety, but could also stifle innovation. Legal uncertainty for developers is compounded where software applications are made available globally (implicating multiple regulatory frameworks), and directly to lay users. Moreover, there is considerable uncertainty over the application of (evolving) medical device regulations in the context of both software and genetics. In this article, criteria and examples are provided to inform determinations of software as medical devices, as well as risk classification. We conclude with strategies for using genomic communication and interpretation software to maximize the availability and usefulness of genetic information, while mitigating the risk of harm to users.

[1]  Barbara Evans,et al.  The Challenge of Regulating Clinical Decision Support Software After 21st Century Cures , 2018, American Journal of Law & Medicine.

[2]  T. Dent,et al.  Risk stratification, genomic data and the law , 2018, Journal of Community Genetics.

[3]  Stephanie M. Fullerton,et al.  “Bridge to the Literature”? Third-Party Genetic Interpretation Tools and the Views of Tool Developers , 2018, Journal of Genetic Counseling.

[4]  G. Marchant,et al.  Physicians' duty to recontact and update genetic advice. , 2017, Personalized medicine.

[5]  Paul Quinn The EU commission's risky choice for a non-risk based strategy on assessment of medical devices , 2017, Comput. Law Secur. Rev..

[6]  Trevor J Pugh,et al.  Data resources for the identification and interpretation of actionable mutations by clinicians , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Robert Cook-Deegan,et al.  Public variant databases: liability? , 2016, Genetics in Medicine.

[8]  Clarification of When Products Made or Derived From Tobacco Are Regulated as Drugs, Devices, or Combination Products; Amendments to Regulations Regarding "Intended Uses." Final rule. , 2017, Federal register.

[9]  Elizabeth R. Pike,et al.  Consuming Genomics: Regulating Direct-to-Consumer Genetic and Genomic Information , 2014 .

[10]  Nancy G. Leveson,et al.  An investigation of the Therac-25 accidents , 1993, Computer.

[11]  T. H. Allegri The Code of Federal Regulations , 1986 .